Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Prevalence and features of metabolic syndrome in childhood-onset systemic lupus erythematosus

Full text
Author(s):
Sinicato, Nailu Angelica ; Postal, Mariana ; Pelicari, Karina de Oliveira ; Rittner, Leticia ; Marini, Roberto ; Appenzeller, Simone
Total Authors: 6
Document type: Journal article
Source: CLINICAL RHEUMATOLOGY; v. 36, n. 7, p. 1527-1535, JUL 2017.
Web of Science Citations: 1
Abstract

To estimate the prevalence and features of metabolic syndrome (MetS) in childhood-onset systemic lupus erythematosus (cSLE), we performed a cross-sectional study of 76 consecutive cSLE patients and 54 healthy controls, age and sex matched. All individuals were assessed for anthropometric and MetS features according to World Health Organization (WHO), NCEP Adult Treatment Panel III (NCEP-ATP III), and International Diabetes Federation (IDF) criteria. The cSLE patients were further assessed for clinical and laboratory manifestations, disease activity (Systemic Lupus Erythematosus Disease Activity Index), cumulative damage (Systemic Lupus International Collaborating Clinics (SLICC)), and current and cumulative drug exposures. Sixty-nine (90.8%) patients were female with mean age of 16.8 years {[}standard deviation (SD) +/- 4.0 years]. Mean disease duration was 4.8 years (SD +/- 4.1). Based on the WHO MetS criteria, MetS was observed in two (2.6%) cSLE patients. We observed high prevalence of the MetS in cSLE patients according to NCEP-ATP III MetS criteria (18.4%) (p = 0.002) and according to IDF MetS criteria (17.1%) (p = 0.003). We did not observe MetS in the control group. No difference in cSLE patients < 18 and 18 years was observed. We observed an association between the presence of MetS and SLICC scores in cSLE < 18 years and cumulative corticosteroid dose adjusted by weight in cSLE 18 years. This study showed that MetS is frequently observed in cSLE using NCEP-ATP III MetS criteria and IDF MetS criteria. The identification of MetS is important to indicate cardiovascular morbidity and mortality in cSLE. (AU)

FAPESP's process: 09/06049-6 - Blood and cerebrospinal fluid biomarkers associated with structural and functional central nervous system abnormalities in Systemic lupus erythematosus
Grantee:Simone Appenzeller
Support Opportunities: Scholarships in Brazil - Young Researchers
FAPESP's process: 09/15286-1 - PREVALENCE AND FACTORS ASSOCIATED WITH THE METABOLIC SYNDROME IN YOUNG SYSTEMIC LUPUS ERYTEMATOSUS
Grantee:Nailú Angélica Sinicato Martin
Support Opportunities: Scholarships in Brazil - Scientific Initiation
FAPESP's process: 08/02917-0 - Blood and cerebrospinal fluid biomarkers associated with structural and functional central nervous system abnormalities in systemic lupus erythematosus
Grantee:Simone Appenzeller
Support Opportunities: Research Grants - Young Investigators Grants